Accendra Health, Inc. (ACH) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $3.09 (+1.82%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 22, 2026 | Kevin Caliendo | UBS | $3.00 | -2.9% |
| Jan 6, 2026 | Eric Coldwell | Robert W. Baird | $5.00 | +61.8% |
| Nov 3, 2025 | Kevin Caliendo | UBS | $4.00 | +29.4% |
| Aug 13, 2025 | Kevin Caliendo | UBS | $7.00 | +126.5% |
| Aug 11, 2025 | Michael Minchak | J.P. Morgan | $10.00 | +223.6% |
| Aug 8, 2025 | Eric Coldwell | Robert W. Baird | $10.00 | +223.6% |
| Nov 5, 2024 | Eric Coldwell | Robert W. Baird | $14.00 | +353.1% |
| Sep 23, 2024 | Eric Coldwell | Robert W. Baird | $19.00 | +514.9% |
| Jun 25, 2024 | Michael Cherny | Leerink Partners | $17.00 | +450.2% |
| Jun 25, 2024 | Eric Coldwell | Robert W. Baird | $20.00 | +547.2% |
| May 6, 2024 | Eric Coldwell | Robert W. Baird | $24.00 | +676.7% |
| Apr 10, 2024 | Eric Coldwell | Robert W. Baird | $28.00 | +806.1% |
| Oct 12, 2022 | Eric Coldwell | Robert W. Baird | $22.00 | +612.0% |
| May 8, 2022 | Kevin Caliendo | UBS | $54.00 | +1647.6% |
Top Analysts Covering ACH
ACH vs Sector & Market
| Metric | ACH | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.40 | 2.24 | 2.40 |
| Analyst Count | 5 | 8 | 19 |
| Target Upside | +61.0% | +11475.0% | +17.1% |
| P/E Ratio | -0.27 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.58B | $2.59B | $2.64B | 4 |
| 2027-03-31 | $654M | $661M | $668M | 3 |
| 2027-06-30 | $643M | $651M | $658M | 2 |
| 2027-09-30 | $660M | $668M | $675M | 2 |
| 2027-12-31 | $675M | $683M | $690M | 3 |
| 2028-03-31 | $717M | $725M | $733M | 2 |
| 2028-06-30 | $684M | $692M | $700M | 1 |
| 2028-09-30 | $699M | $707M | $715M | 1 |
| 2028-12-31 | $717M | $725M | $733M | 2 |
| 2029-12-31 | $3.16B | $3.22B | $3.27B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.59 | $0.70 | $0.81 | 3 |
| 2027-03-31 | $0.16 | $0.16 | $0.16 | 1 |
| 2027-06-30 | $0.26 | $0.26 | $0.26 | 1 |
| 2027-09-30 | $0.32 | $0.33 | $0.33 | 1 |
| 2027-12-31 | $0.49 | $0.50 | $0.51 | 1 |
| 2028-03-31 | $0.23 | $0.24 | $0.24 | 1 |
| 2028-06-30 | $0.29 | $0.29 | $0.29 | 1 |
| 2028-09-30 | $0.35 | $0.36 | $0.36 | 1 |
| 2028-12-31 | $0.55 | $0.56 | $0.57 | 1 |
| 2029-12-31 | $1.08 | $1.11 | $1.13 | 1 |
Frequently Asked Questions
What is the analyst consensus for ACH?
The consensus among 5 analysts covering Accendra Health, Inc. (ACH) is Buy with an average price target of $5.25.
What is the highest price target for ACH?
The highest price target for ACH is $54.00, set by Kevin Caliendo at UBS on 2022-05-08.
What is the lowest price target for ACH?
The lowest price target for ACH is $3.00, set by Kevin Caliendo at UBS on 2026-02-22.
How many analysts cover ACH?
5 analysts have issued ratings for Accendra Health, Inc. in the past 12 months.
Is ACH a buy or sell right now?
Based on 5 analyst ratings, ACH has a consensus rating of Buy (2.40/5) with a +61.0% upside to the consensus target of $5.25.
What are the earnings estimates for ACH?
Analysts estimate ACH will report EPS of $0.70 for the period ending 2026-12-31, with revenue estimated at $2.59B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.